12.5
12.50 (0.41%)
As of Mar 06, 2024
Precision Biosciences Inc [DTIL]
Source:
Company Overview
We are a clinical stage gene editing company dedicated to improving life by developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of our wholly owned proprietary ARCUS genome editing platform. The foundation of ARCUS is a natural homing endonuclease which allows us to replicate precise gene editing as it evolved in nature.
Country | United States |
Headquarters | durham, north carolina |
Phone Number | 919-314-5512 |
Industry | manufacturing |
CEO | Michael Amoroso |
Website | www.precisionbiosciences.com |